Patterns and perceptions of supplement use among patients with plasma cell disorders
As novel treatments have improved survival in patients with plasma cell disorders (PCDs), there is a growing interest in complementary medicine (CM), particularly dietary supplements (vitamins, minerals, antioxidants, and herbs), amongst patients with cancer [ 1 ]. Multiple myeloma (MM) and its precursor conditions (monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)) provide opportunities for CM, as the standard practice for precursor conditions is observation while MM requires long term treatment – during which supportive strategies may improve treatment tolerance, response, and quality of life [ 2 ].
Authors
- Patricia Alejandra Flores Pérez
- Saad Z. Usmani (ORCID: https://orcid.org/0000-0002-5484-8731)
- Ana M. Aldana (ORCID: https://orcid.org/0000-0003-3439-6245)
- Jennifer M. Ahlstrom
- Urvi Ashok Shah (ORCID: https://orcid.org/0000-0001-8419-1091)
- Jorge Arturo Hurtado Martínez (ORCID: https://orcid.org/0000-0002-4503-1690)
- Francesca Castro (ORCID: https://orcid.org/0000-0003-2023-5483)
- Andriy Derkach (ORCID: https://orcid.org/0000-0003-2178-8493)
- Maria Malik (ORCID: https://orcid.org/0000-0002-9516-095X)
- Jay R. Hydren
- Yan Leyfman
- Susan Chimonas
- Eliana Schach
- Jun J. Mao
Institutions
- Albert Einstein College of Medicine (US)
- Memorial Sloan Kettering Cancer Center (US)
- Montefiore Medical Center (US)
- NewYork–Presbyterian Brooklyn Methodist Hospital (US)
- New York University (US)
Publication Details
- Journal
- Blood Cancer Journal
- Published
- 2026-08-14
- DOI
- https://doi.org/10.1038/s41408-026-01603-x
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- Sanofi
- Gilead Sciences
- Celgene
- Memorial Sloan-Kettering Cancer Center
- Array BioPharma
- National Institutes of Health
- Genentech
- NYU Grossman School of Medicine
- National Cancer Institute